The drug demonstrates potent inhibitory effects on pEGFR levels in H3255, HCC827, and H1975 cell lines, leading to effective inhibition of cell proliferation.173–176 Although the sponsor withdrew the study of nazartinib and erlotinib/gefitinib in the first-line treatment of locally advanced/metastatic NSCLC with EGFR mutations (NCT03529084) in 2019. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.